GeneBioTech Co Ltd

GeneBioTech maintains a conservative capital structure with a debt-to-equity ratio of 0.27 and a current ratio of 3.48, indicating strong short-term liquidity. However, the company reports negative net cash after subtracting total debt, signaling potential liquidity constraints. The price-to-book ratio of 0.73 suggests the market values the company below its book value, while the price-to-earnings ratio of 10.6 reflects a moderate valuation relative to earnings. Profitability metrics show a return on equity (ROE) of 6.89% and return on assets (ROA) of 5.01%, both below the typical thresholds for high-growth pharmaceutical firms. The gross margin of 15.85% (computed as gross profit / revenue) is in line with industry norms, but the operating margin of 4.32% (operating income / revenue) indicates pressure from cost of goods sold and operating expenses. The company operates through two segments: Additive and Animal Drug. Revenue concentration data is not disclosed, but the company serves both domestic and international markets, including the Americas. This geographic diversification may mitigate regional economic risks but could also expose the company to currency and regulatory volatility. Outlook data is not provided for future revenue or earnings, but historical revenue of KRW 90.8 billion and net income of KRW 3.8 billion suggest stable performance. The company's capital expenditure of KRW -3.8 billion indicates a net cash inflow from investing activities, potentially signaling a reduction in investment or asset sales. Risk factors include medium liquidity risk due to negative net cash and low dilution risk. The company has not disclosed any recent equity issuance or dilutive events, and the risk assessment does not flag imminent dilution pressure. No recent filings or transcripts are provided to assess management commentary or strategic shifts.